The U.S. Food and Drug Administration (FDA) has approved the ConcizuTrace™ ELISA Companion Diagnostic (CDx) test, which helps to determine the amount of concizumab-mtci that is circulating in an individual who has taken the product.Concizumab-mtci…
The National Bleeding Disorders Foundation (NBDF) is delighted to announce a new accredited education opportunity for health care providers focused on personalized care for individuals with von Willebrand disease (VWD).“Restoring Control in…
Shelly Reed is a senior training specialist at HUB International, where she develops and delivers technical training. With an extensive background in learning and development, she has a passion for leveraging technology to innovate learning programs…
Dr. Christy Miller is a two-time graduate of the College of Saint Rose with a dual degree BS in early childhood education and early childhood special education, and an MEd in professional special education. She also completed a Ph.D. in…
Daniel Abraham is a dedicated advocate for the bleeding disorders community who balances two distinct careers: a professional actor and performer, and a lead software developer for a small tech firm. A man with severe hemophilia A, he has championed…
Sammie is a highly regarded member of the inheritable bleeding disorders community and a lived experience expert. Diagnosed with von Willebrand disease (VWD) at the age of 32, she navigates her personal journey with remarkable resilience. Beyond…
Sundar Selvaraj is a research specialist at the University of Michigan, Ann Arbor, MI, focusing on biomedical research on factor VIII and hemophilia A. Diagnosed with an ultra rare combination of severe factor XIII deficiency and type 2 M von…
Raymond “Ray” Stanhope LEE (Lived Experience Expert), President of the Lone Star Bleeding Disorders Foundation and Co-Chair LEE WG for the National Research Blueprint (NRB), he is a person living with severe hemophilia B. For over 30 years, he has…
Dr. Singleton, speaking on behalf of HEMA Biologics, will discuss a treatment option for patients 12 years of age or older with hemophilia A or B with inhibitors. Sponsored by HEMA Biologics.Speakers: Tammuella “Tami” Chrisentery-…
Sanofi invites you to join an educational symposium where Dr. Jain will introduce a new rebalancing subcutaneous injection treatment for hemophilia A and B. This presentation will cover the benefits and safety of this new treatment, as well as how…